Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · IEX Real-Time Price · USD
11.32
+0.22 (1.98%)
At close: May 17, 2024, 4:00 PM
11.86
+0.54 (4.77%)
After-hours: May 17, 2024, 6:43 PM EDT
MRVI Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for MRVI stock have an average target of 11.44, with a low estimate of 7.00 and a high estimate of 17. The average target predicts an increase of 1.06% from the current stock price of 11.32.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MRVI stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 4 | 4 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | -11.66% | May 9, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +32.51% | Apr 10, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $12 → $14 | Buy | Maintains | $12 → $14 | +23.67% | Feb 23, 2024 |
| Stifel | Stifel | Strong Buy Maintains $11 → $10 | Strong Buy | Maintains | $11 → $10 | -11.66% | Feb 23, 2024 |
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $10 → $8 | Hold → Strong Buy | Upgrades | $10 → $8 | -29.33% | Dec 12, 2023 |
Financial Forecast
Revenue This Year
277.57M
from 288.95M
Decreased by -3.94%
Revenue Next Year
305.14M
from 277.57M
Increased by 9.93%
EPS This Year
-0.02
from -0.90
EPS Next Year
0.05
from -0.02
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 291.7M | 345.8M | 424.8M | 460.1M | 575.1M |
| Avg | 277.6M | 305.1M | 353.3M | 447.0M | 558.7M |
| Low | 259.7M | 279.0M | 303.8M | 429.4M | 536.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.0% | 24.6% | 39.2% | 30.2% | 28.7% |
| Avg | -3.9% | 9.9% | 15.8% | 26.5% | 25.0% |
| Low | -10.1% | 0.5% | -0.4% | 21.6% | 20.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.03 | 0.13 | 0.16 | 0.23 | 0.39 |
| Avg | -0.02 | 0.05 | 0.11 | 0.22 | 0.38 |
| Low | -0.06 | -0.01 | 0.05 | 0.22 | 0.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 220.5% | 105.9% | 73.1% |
| Avg | - | - | 128.3% | 100.0% | 68.2% |
| Low | - | - | -0.3% | 92.2% | 61.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.